Skip to main content
Terug
Watch Compare

Marker Therapeutics, Inc.

Datakwaliteit: 83%
MRKR
NASDAQ Manufacturing Chemicals
€ 1,70
▼ € 0,05 (-2,86%)
Marktkapitalisatie: 22,64 M
Prijs
€ 1,75
Marktkapitalisatie
22,64 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -12,01 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-84,24%
Onder sectorgemiddelde (-54,47%)
ROIC-70,52%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio6,50
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-1,86 | -9,21
Onder sectorgemiddelde (-1,49)
P/B Ratio1,23
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -1,9 -1,5
P/B 1,2 1,6
ROE % -84,2 -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

3 analisten
Buy
Huidig
€ 1,70
+362.7%
Koersdoel
€ 7,87
€ 5,60
€ 8,00
€ 10,00
Vooruitzicht
Forward K/W -9,21
Forward WPA -€ 0,19
Omzet Sch. 20,05 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,19
-€ 0,19 – -€ 0,19
 20,05 M 1
FY2026 -€ 0,61
-€ 0,61 – -€ 0,61
 2,70 M 1

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,19 -€ 0,04 +79,0%
Q32025 -€ 0,21 -€ 0,12 +42,9%
Q22025 -€ 0,27 -€ 0,29 -7,4%
Q12025 -€ 0,66 -€ 0,40 +39,4%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -12,16 M
ROE -84,24% ROA -66,65%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -12,01 M
ROIC -70,52% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 6,50
Interest Coverage N/A Asset Turnover N/A
Working Capital 18,39 M Tangible Book Value 18,39 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,86 Forward P/E -9,21
P/B Ratio 1,23 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 1,13 Fwd Earnings Yield N/A
FCF Yield -53,06%
Market Cap 22,64 M Enterprise Value 5,05 M
Per Share
EPS (Diluted TTM) -0,79 Revenue / Share N/A
FCF / Share -0,93 OCF / Share -0,93
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 98,77%
SBC-Adj. FCF -12,49 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — 0,0
Net Income -12,16 M -10,73 M -8,24 M -29,93 M -41,88 M
EPS (Diluted) -0,79 -1,19 -0,94 -3,58 -0,55
Gross Profit — — — — —
Operating Income -12,89 M -11,12 M -14,58 M -29,95 M -39,48 M
EBITDA — — — — —
R&D Expenses 11,80 M 13,47 M 10,42 M 26,14 M 27,79 M
SG&A Expenses — — — — —
D&A — — — 2,79 M 2,15 M
Interest Expense — — — — —
Income Tax -15.156,0 49.953,0 3.675,0 — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 19,07 M 22,02 M 17,13 M 34,42 M 68,14 M
Total Liabilities 2,27 M 3,46 M 3,07 M 14,82 M 24,15 M
Shareholders' Equity 16,80 M 18,56 M 14,05 M 19,60 M 43,99 M
Total Debt — — — — —
Cash & Equivalents 16,07 M 19,19 M 15,11 M 11,78 M 42,35 M
Current Assets 19,07 M 22,02 M 17,13 M 16,62 M 45,98 M
Current Liabilities 2,27 M 3,46 M 3,07 M 7,78 M 12,90 M